Business · 22/04/2015
FDA Releases Guidance for Clinical Trial Endpoints in Non-Small Cell Lung Cancer Drug Approvals
The FDA has finalized a guidance document outlining recommended endpoints for clinical trials of non-small cell lung cancer drugs and biologics to support effectiveness claims in new drug applications and other FDA submissions.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →